ResultsIQ

ResultsIQ › Latest results › Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited Q1 FY27 results deck summary

NSE: GUJTHEM · BSE: 506879

Results deck of 7 Aug 2026, summarised by AI from the filing.

Q1 FY27 revenue grew 22.1% to ₹43.8 cr, EBITDA rose 49.4% to ₹20.8 cr, PAT improved 22.1% to ₹11.1 cr.

Key takeaways

  1. Q1 FY27 results Top line grew 22.1% year-on-year to ₹43.8 cr; EBITDA increased 49.4% to ₹20.8 cr; PAT improved 22.1% to ₹11.1 cr.
  2. Acquisition close MicroBiopharm Japan acquisition expected to close Q2 FY2027, subject to regulatory approvals.
  3. Inorganic expansion Acquisition of Sanofi's brands and MicroBiopharm in Japan widen therapy areas and geographical reach.
  4. Growth driver Healthy sales volumes and optimized production drove top line; higher volumes helped offset employee & other costs, boosting EBITDA margins.
  5. Risk MicroBiopharm acquisition close is subject to regulatory approvals.

Original filing on BSE

Gujarat Themis Biosyn Limited Q1 FY27 results

As filed: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.